Deep Learning Dose Prediction Models Catalogue

DEEP LEARNING DOSE PREDICTION MODELS

TABLE OF CONTENTS

DEEP LEARNING DOSE PREDICTION MODELS Brain RSL Brain Proton.............................................................................................. 4

Breast RSL Breast Left................................................................................................ 5 RSL Breast Left 2LVS...................................................................................... 6 RSL Breast Locoregional 2LVS..................................................................... 7

Head and neck RSL Oropharynx Proton 2LVS....................................................................... 8 RSL Oropharynx 2LVS.................................................................................... 9 RSL Oropharynx 3LVS..................................................................................10

Lung RSL Lung SBRT...............................................................................................11

Prostate RSL Prostate...................................................................................................12 RSL ProstateBed SVs Nodes 2LVS............................................................13 RSL Prostate SVs Nodes 2LVS....................................................................14 RSL Prostate 3LVS.........................................................................................15

Rectum RSL Rectum....................................................................................................16

MACHINE LEARNING FASTER AND SMARTER TREATMENT PLANNING Generate treatment plans automatically with deep learning driven dose prediction. RaySearch provides your clinic with a roster of machine learning models that have been validated against common radiotherapy treatment protocols. Details about the treatment protocols can be found in the respective model data sheets.

RaySearch can help your clinic adapt the post-processing of the dose prediction and the optimization settings to match your protocols, clinical priorities and treatment machines.

Read more about Machine Learning on our website: www.raysearchlabs.com

Continue to next page to view the models >

RSL BRAIN PROTON*

Validation patient example

MODEL OVERVIEW

MODEL PROTOCOL

Treatment site

Brain

ROI

Clinical goals

Modality

Protons

CTV

At least 4738 cGy dose at 98.0 % volume

Treatment technique

Validated for pencil beam scanning

CTV

At least 4788 cGy dose at 98.0 % volume

CTV

At most 5494 cGy dose at 0.03 cm3 volume

Primary prescription [cGy]

5040

CTV

At most 5394 cGy dose at 0.03 cm3 volume

Number of fractions

28

Brain

At most 5860 cGy dose at 0.03 cm3 volume

Dose per fraction [cGy]

180

Brainstem core

At most 5470 cGy dose at 0.03 cm3 volume

Brainstem surface

At most 5860 cGy dose at 0.03 cm3 volume

Optic chiasm

At most 5530 cGy dose at 0.03 cm3 volume

Optic nerve L/R

At most 5530 cGy dose at 0.03 cm3 volume

Spinal cord

At most 3190 cGy dose at 0.03 cm3 volume

Retina L/R

At most 4780 cGy dose at 0.03 cm3 volume

Cornea L/R

At most 3580 cGy dose at 0.03 cm3 volume

Cochlea L/R

At most 3700 cGy average dose

Hippocampus L/R

At most 40% volume at 1200 cGy dose

Lacrimal gland L/R

At most 3060 cGy average dose

Pituitary

At most 2700 cGy average dose

Pituitary

At most 4830 cGy average dose

Skin

At most 3190 cGy dose at 0.03 cm3 volume

* Subject to regulatory clearance in some markets. Not for marketing in the USA or Canada.

Page 4

RSL BREAST LEFT*

Validation patient example

MODEL OVERVIEW

MODEL PROTOCOL

Treatment site

Breast

ROI

Clinical goals

Modality

Photons

PTV-Skin

At least 3805 cGy dose at 98.0 % volume

Treatment technique

Validated for SMLC

PTV-Skin

At least 4005 cGy average dose

Primary prescription [cGy]

4005

PTV-Skin

At most 4285 cGy dose at 2.0 % volume

Heart

At most 1600 cGy dose at 5.0 % volume

Number of fractions

15

Heart

At most 800 cGy dose at 30.0 % volume

Dose per fraction [cGy]

267

Heart

At most 320 cGy average dose

Lung L

At most 1600 cGy dose at 15.0 % volume

Lung L

At most 800 cGy dose at 35.0 % volume

Lung L

At most 400 cGy dose at 50.0 % volume

Lung R

At most 400 cGy dose at 10.0 % volume

* Subject to regulatory clearance in some markets. Not for marketing in the USA or Canada.

Page 5

RSL BREAST LEFT 2LVS* MODEL OVERVIEW Treatment site

Breast

Modality

Photons

Treatment technique

Validated for VMAT

Primary prescription [cGy]

4800

Number of fractions

16

Dose per fraction [cGy]

300

MODEL PROTOCOL

Validation patient example

* Subject to regulatory clearance in some markets.

Not for marketing in the USA or Canada.

Page 6

ROI

Clinical goals

PTV High

At least 4560 cGy dose at 98.0 % volume

PTV High

At most 4944 cGy dose at 2.0 % volume

PTV High

At least 96.0 % volume at 4560 cGy dose

PTV High

At most 1.0 % volume at 5040 cGy dose

PTV Low

At least 3940 cGy dose at 98.0 % volume

PTV Low-PTV High

At most 4800 cGy dose at 1.0 % volume

PTV Low

At least 95.0 % volume at 4028 cGy dose

PTV Low-PTV High

At most 15.0 % volume at 4452 cGy dose

PTV High

At least a conformity index of 0.8 at 4560 cGy isodose

PTV High

At least a homogeneity index of 0.9 at 98.0 % volume

PTV Low

At least a conformity index of 0.85 at 4028 cGy isodose

PTV Low

At least a homogeneity index of 0.8 at 95.0 % volume

Lung L

At most 25.0 % volume at 500 cGy dose

Lung L

At most 15.0 % volume at 1000 cGy dose

Lung L

At most 7.0% volume at 2000 cGy dose

Lung L

At most 1.0 % volume at 4000 cGy dose

Lung L

At most 600 cGy average dose

Lung R

At most 100 cGy average dose

Lung R

At most 400 cGy dose at 1.0 % volume

Heart

At most 150 cGy average dose

Heart

At most 500 cGy dose at 1.0 % volume

Breast R

At most 200 cGy average dose

Breast R

At most 700 cGy dose at 1.0 % volume

A Coronary L

At most 200 cGy dose at 1.0 % volume

Humerus L

At most 200 cGy average dose

Brachial Plexus L

At most 4240 cGy dose at 0.0 % volume

Liver

At most 200 cGy dose at 0.0 % volume

Spinal Canal

At most 200 cGy dose at 0.0 % volume

RSL BREAST LOCOREGIONAL 2LVS*

Validation patient example

MODEL OVERVIEW

MODEL PROTOCOL

Treatment site

Breast (or thoracic wall) and nodes

Modality

Photons

Treatment technique

Validated for VMAT

Primary prescription [cGy]

6000

Number of fractions Dose per fraction [cGy]

Clinical goals varied based on primary target (either breast or thoracic wall) and the involved lymph nodes. Clinical goal values given in the table below represent the ones used for breast with all lymph nodes involved.

ROI

Clinical goals

PTV1

At least 5989 cGy average dose

PTV1

At least 5700 cGy dose at 99.1 % volume

25

PTV1

At most 6180 cGy dose at 0.5 % volume

240

PTV2

At least 4750 cGy dose at 98.4 % volume

PTV2-PTV1

At most 5250 cGy dose at 9.6 % volume

PTV3

At least 4750 cGy dose at 99.2 % volume

PTV3

At most 5250 cGy dose at 0 % volume

PTV4

At least 4750 cGy dose at 96.0 % volume

PTV4

At most 5250 cGy dose at 0.1 % volume

PTV5

At least 4750 cGy dose at 98.0 % volume

PTV5

At most 5250 cGy dose at 0.1 % volume

PTV6

At least 4750 cGy dose at 96.2 % volume

PTV6

At most 5250 cGy dose at 0.6 % volume

Organs at risk

Clinical goals varied based on primary target volume and lymph node involvement

* Subject to regulatory clearance in some markets. Not for marketing in the USA or Canada.

Page 7

RSL OROPHARYNX PROTON 2LVS* MODEL PROTOCOL

Validation patient example

MODEL OVERVIEW Treatment site

Head and neck

Modality

Protons

Treatment technique

Validated for pencil beam scanning

Primary prescription cGy [RBE]

7000

Number of fractions

35

Dose per fraction cGy [RBE]

200

* Subject to regulatory clearance in some markets. Not for marketing in the USA or Canada.

Page 8

ROI

Clinical goals

CTV High

At least 6650 cGy dose at 98.0 % volume

CTV High

At most 7490 cGy dose at 0.0 % volume

CTV Low

At least 5154 cGy dose at 98.0 % volume

CTV Low

At least 5100 cGy dose at 98.0 % volume

CTV High

At least 6580 cGy dose at 98.0 % volume

Spinal Cord

At most 4500 cGy dose at 0.0 % volume

Brain

At most 5800 cGy dose at 1.0 cm³ volume

Brain

At most 6800 cGy dose at 0.0 % volume

Cochlea L/R

At most 4500 cGy dose at 50.0 % volume

Cochlea L/R

At most 5500 cGy dose at 5.0 % volume

Parotid L/R

At most 2600 cGy dose at 50.0 % volume

Constrictor Muscle I/M/S

At most 5500 cGy dose at 50.0 % volume

Brainstem

At most 5400 cGy dose at 0.0 % volume

Submandibular Gland L/R

At most 3500.0 cGy dose at 50.0 % volume

Cavity Oral

At most 3000 cGy dose at 50.0 % volume

Esophagus S

At most 3000 cGy dose at 50.0 % volume

Optic Nerve L/R

At most 5400 cGy dose at 0.0 % volume

Eye L/R

At most 3000 cGy dose at 0.0 % volume

Lacrimal Gland L/R

At most 2500 cGy dose at 50.0 % volume

Glottis

At most 4000 cGy dose at 50.0 % volume

Larynx SG

At most 4000 cGy dose at 50.0 % volume

Bone Mandible

At most 7200 cGy dose at 0.0 % volume

RSL OROPHARYNX 2LVS* MODEL PROTOCOL

Validation patient example

MODEL OVERVIEW Treatment site

Head and neck

Modality

Photons

Treatment technique

Validated for VMAT

Primary prescription [cGy]

7000

Number of fractions

35

Dose per fraction [cGy]

200

* Subject to regulatory clearance in some markets. Not for marketing in the USA or Canada.

Page 9

ROI

Clinical goals

PTV High

At least 6650 cGy dose at 98.0 % volume

PTV High

At most 7490 cGy dose at 1.8 cm³ volume

PTV Low

At least 5320 cGy dose at 98.0 % volume

Spinal Cord

At most 4500 cGy dose at 0.0 % volume

Brain

At most 5800 cGy dose at 1.0 cm³ volume

Brain

At most 6800 cGy dose at 0.0 % volume

Cochlea L/R

At most 4500 cGy dose at 50.0 % volume

Cochlea L/R

At most 5500 cGy dose at 5.0 % volume

Parotid L/R

At most 2600 cGy dose at 50.0 % volume

Constrictor Muscle I/M/S

At most 5500 cGy dose at 50.0 % volume

Brainstem

At most 5400 cGy dose at 0.0 % volume

Submandibular Gland L/R

At most 3500 cGy dose at 50.0 % volume

Cavity Oral

At most 3000 cGy dose at 50.0 % volume

Esophagus S

At most 3000 cGy dose at 50.0 % volume

Optic Nerv L/R

At most 5400 cGy dose at 0.0 % volume

Eye L/R

At most 3000 cGy dose at 0.0 % volume

Lacrimal Gland L/R

At most 2500 cGy dose at 50.0 % volume

Glottis

At most 4000 cGy dose at 50.0 % volume

Larynx SG

At most 4000 cGy dose at 50.0 % volume

Bone Mandible

At most 7200 cGy dose at 0.0 % volume

RSL OROPHARYNX 3LVS* MODEL PROTOCOL

Validation patient example

MODEL OVERVIEW Treatment site

Head and neck

Modality

Photons

Treatment technique

Validated for VMAT

Primary prescription [cGy]

6600

Number of fractions

33

Dose per fraction [cGy]

200

* Subject to regulatory clearance in some markets. Not for marketing in the USA or Canada.

Page 10

ROI

Clinical goals

PTV High

At least 6270 cGy dose at 98.0 % volume

PTV High

At most 7062 cGy dose at 1.8 cm³ volume

PTV Mid

At least 5700 cGy dose at 98 % volume

PTV Low

At least 4750 cGy dose at 98.0 % volume

Spinal Cord

At most 4500 cGy dose at 0.0 % volume

Brain

At most 5800 cGy dose at 1.0 cm³ volume

Brain

At most 6800 cGy dose at 0.0 % volume

Cochlea L/R

At most 4500 cGy dose at 50.0 % volume

Cochlea L/R

At most 5500 cGy dose at 5.0 % volume

Parotid L/R

At most 2600 cGy dose at 50.0 % volume

Constrictor Muscle I/M/S

At most 5500 cGy dose at 50.0 % volume

Brainstem

At most 5400 cGy dose at 0.0 % volume

Submandibular Gland L/R

At most 3500 cGy dose at 50.0 % volume

Cavity Oral

At most 3000 cGy dose at 50.0 % volume

Esophagus S

At most 3000 cGy dose at 50.0 % volume

Optic Nerv L/R

At most 5400 cGy dose at 0.0 % volume

Eye L/R

At most 3000 cGy dose at 0.0 % volume

Lacrimal Gland L/R

At most 2500 cGy dose at 50.0 % volume

Glottis

At most 4000 cGy dose at 50.0 % volume

Larynx SG

At most 4000 cGy dose at 50.0 % volume

Bone Mandible

At most 7200 cGy dose at 0.0 % volume

RSL LUNG SBRT*

Validation patient example

MODEL OVERVIEW

MODEL PROTOCOL

Treatment site

Lung

ROI

Clinical goals

Modality

Photons

PTV

At least 99.0 % volume at 4320 cGy dose

Treatment technique

Validated for VMAT

PTV

At least 95.0 % volume at 4800 cGy dose

Primary prescription [cGy]

4800

PTV

At most 8000 cGy dose at 0.0 % volume

Spinal Canal

At most 2600 cGy dose at 0.03 cm³ volume

Number of fractions

4

Spinal Canal

At most 2080 cGy dose at 0.35 cm³ volume

1200

Spinal Canal

At most 1360 cGy dose at 1.2 cm³ volume

Esophagus

At most 3000 cGy dose at 0.03 cm³ volume

Esophagus

At most 1880 cGy dose at 5.0 cm³ volume

Heart

At most 3400 cGy dose at 0.03 cm³ volume

Heart

At most 2800 cGy dose at 15.0 cm³ volume

Trachea

At most 1560 cGy dose at 4.0 cm³ volume

Trachea

At most 3480 cGy dose at 0.03 cm³ volume

Skin

At most 3600 cGy dose at 0.03 cm³ volume

Skin

At most 3320 cGy dose at 10.0 cm³ volume

Lungs

At most 10.0 % volume at 2000 cGy dose

Bronchus

At most 3480 cGy dose at 0.03 cm³ volume

Bronchus

At most 1560 cGy dose at 4.0 cm³ volume

Brachial Plexus L/R

At most 2720 cGy dose at 0.03 cm³ volume

Brachial Plexus L/R

At most 2360 cGy dose at 3.0 cm³ volume

Dose per fraction [cGy]

* Subject to regulatory clearance in some markets.

Not for marketing in the USA or Canada.

Page 11

RSL PROSTATE*

Validation patient example

MODEL OVERVIEW

MODEL PROTOCOL

Treatment site

Prostate

ROI

Clinical goals

Modality

Photons

CTV

At least 6000 cGy dose at 99.0 % volume

Treatment technique

Validated for VMAT

PTV

At least 5700 cGy dose at 99.0 % volume

PTV

At most 6300 cGy dose at 1.0 cm³ volume

Primary prescription [cGy]

6000

Bladder Wall

At most 30.0 % volume at 4600 cGy dose

Number of fractions

20

Bladder Wall

At most 50.0 % volume at 3700 cGy dose

300

Rectal Wall

At most 30.0 % volume at 4600 cGy dose

Rectal Wall

At most 50.0 % volume at 3700 cGy dose

Femoral Head L/R

At most 5.0 % volume at 4300 cGy dose

Penile Bulb

At most 5000 cGy average dose

Penile Bulb

At most 150.0 cm³ volume at 5000 cGy dose

Dose per fraction [cGy]

* Subject to regulatory clearance in some markets. Not for marketing in the USA or Canada.

Page 12

RSL PROSTATEBED SVS NODES 2LVS*

Validation patient example

MODEL OVERVIEW

MODEL PROTOCOL

Treatment site

ProstateBed+SVs+Nodes

ROI

Clinical goals

Modality

Photons

PTV High

At least 50.0 % volume at 7700 cGy dose

Treatment technique

Validated for VMAT

PTV High

At least 98.0 % volume at 6650 cGy dose

Primary prescription [cGy]

PTV High

At most 0.03 cm³ volume at 7490 cGy dose

7000

PTV Low

At least 50.0 % volume at 5600 cGy dose

PTV Low

At least 98.0 % volume at 5320 cGy dose

PTV Low-PTV High

At most 0.5 % volume at 5992 cGy dose

Bladder

At most 15.0 % volume at 7000 cGy dose

Bladder

At most 30.0 % volume at 6500 cGy dose

Bladder

At most 60.0 % volume at 4000 cGy dose

Bladder

At most 6500 cGy dose at 50.0 % volume

Bladder

At most 4000 cGy dose at 70.0 % volume

Small Bowel

At most 150.0 cm³ volume at 4500 cGy dose

Femoral Head L/R

At most 5.0 % volume at 5000 cGy dose

Rectum

At most 15.0 % volume at 7000 cGy dose

Rectum

At most 6500 cGy dose at 35.0 % volume

Rectum

At most 40.0 % volume at 6000 cGy dose

Rectum

At most 55.0% volume at 4000 cGy dose

Rectum

At most 80.0 % volume at 3000 cGy dose

Rectum

At most 30.0 % volume at 6500 cGy dose

Number of fractions

35

Dose per fraction [cGy]

200

* Subject to regulatory clearance in some markets.

Not for marketing in the USA or Canada.

Page 13

RSL PROSTATE SVS NODES 2LVS* MODEL OVERVIEW Treatment site

Prostate, seminal vesicles and nodes

Modality

Photons

Treatment technique

Validated for VMAT

Primary prescription [cGy]

7700

Number of fractions

35

Dose per fraction [cGy]

220

MODEL PROTOCOL

Validation patient example

* Subject to regulatory clearance in some markets.

Not for marketing in the USA or Canada.

Page 14

ROI

Clinical goals

PTV High

At least 50.0 % volume at 7700.0 cGy dose

PTV High

At least 98.0 % volume at 7315.0 cGy dose

PTV Low

At least 98.0 % volume at 5320.0 cGy dose

PTV Low

At least 50.0 % volume at 5600.0 cGy dose

Bladder

At most 15.0 % volume at 7000.0 cGy dose

Bladder

At most 15.0 % volume at 7900.0 cGy dose

Bladder

At most 25.0 % volume at 7400.0 cGy dose

Bladder

At most 30.0 % volume at 6500.0 cGy dose

Bladder

At most 35.0 % volume at 6900.0 cGy dose

Bladder

At most 50.0 % volume at 6400.0 cGy dose

Bladder

At most 60.0 % volume at 4000.0 cGy dose

Rectum

At most 3.0 % volume at 7500.0 cGy dose

Rectum

At most 15.0 % volume at 7000.0 cGy dose

Rectum

At most 15.0 % volume at 7400.0 cGy dose

Rectum

At most 25.0 % volume at 6900.0 cGy dose

Rectum

At most 30.0 % volume at 6500.0 cGy dose

Rectum

At most 35.0 % volume at 6400.0 cGy dose

Rectum

At most 40.0 % volume at 6000.0 cGy dose

Rectum

At most 50.0 % volume at 5900.0 cGy dose

Rectum

At most 55.0 % volume at 5000.0 cGy dose

Rectum

At most 65.0 % volume at 4000.0 cGy dose

Rectum

At most 80.0 % volume at 3000.0 cGy dose

Small Bowel

At most 150.0 cm³ volume at 4500.0 cGy dose

Penile Bulb

At most 5100.0 cGy average dose

Femoral Head L/R

At most 5.0 % volume at 5000.0 cGy dose

RSL PROSTATE 3LVS* MODEL OVERVIEW Treatment site

Prostate

Modality

Photons

Treatment technique

Validated for VMAT

Primary prescription [cGy]

6000

Number of fractions

20

Dose per fraction [cGy]

300

MODEL PROTOCOL

Validation patient example

* Subject to regulatory clearance in some markets.

Not for marketing in the USA or Canada.

Page 15

ROI

Clinical goals

PTV High

At least 5700 cGy dose at 99.0 % volume

PTV Mid

At least 5470 cGy dose at 99.0 % volume

PTV Low

At least 4560 cGy dose at 99.0 % volume

PTV Mid-PTV High

At least 5760 cGy dose at 50.0 % volume

PTV Low-PTV Mid

At least 4800 cGy dose at 50.0 % volume

PTV Low-PTV Mid

At most 5470 cGy dose at 3.0 % volume

PTV Mid

At least 99.5 % volume at 5470 cGy dose

PTV Low

At least 99.7 % volume at 4560 cGy dose

Bladder

At most 4079 cGy dose at 50.0 % volume

Bladder

At most 4860 cGy dose at 25.0 % volume

Bladder

At most 6000 cGy dose at 5.0 % volume

Rectum

At most 2460 cGy dose at 80.0 % volume

Rectum

At most 3240 cGy dose at 70.0 % volume

Rectum

At most 4079 cGy dose at 60.0 % volume

Rectum

At most 4860 cGy dose at 50.0 % volume

Rectum

At most 5280 cGy dose at 30.0 % volume

Rectum

At most 5700 cGy dose at 15.0 % volume

Rectum

At most 6000 cGy dose at 3.0 % volume

Femoral Head L/R

At most 4080 cGy dose at 50.0 % volume

Rectum

At most 2420 cGy dose at 60.0 % volume

Rectum

At most 2890 cGy dose at 50.0 % volume

Rectum

At most 4029 cGy dose at 30.0 % volume

Rectum

At most 2070 cGy dose at 70.0 % volume

Penile Bulb

At most 4080 cGy dose at 50.0 % volume

Penile Bulb

At most 4860 cGy dose at 10.0 % volume

Bowel Space

At most 4080 cGy dose at 17.0 cm³ volume

RSL RECTUM*

Validation patient example

MODEL OVERVIEW

MODEL PROTOCOL

Treatment site

Rectum

ROI

Clinical goals

Modality

Photons

PTV

At least 4750 cGy dose at 98.0 % volume

Treatment technique

Validated for VMAT

PTV

At most 5450 cGy dose at 1.0 % volume

Primary prescription [cGy]

5000

PTV

At least 98.0 % volume at 4750 cGy dose

PTV

At most 1.0 % volume at 5350 cGy dose

Number of fractions

20

Bladder

At most 0.1 cm³ volume at 5150 cGy dose

Dose per fraction [cGy]

250

Bladder

At most 35.0 % volume at 4500 cGy dose

Bowel Space

At most 120.0 cm³ volume at 3000 cGy dose

Bowel Space

At most 500.0 cm³ volume at 1500 cGy dose

Femoral Head L/R

At most 0.1 cm³ volume at 5000 cGy dose

Femoral Head L/R

At most 30.0 % volume at 4000 cGy dose

* Subject to regulatory clearance in some markets. Not for marketing in the USA or Canada.

Page 16

Read more about Machine Learning on our website: www.raysearchlabs.com

RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch® markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand®**, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems.

RaySearch software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

*Subject to regulatory clearance in some markets. **RayCommand is not available for use or sale in the USA or Canada.

www.raysearchlabs.com/machine-learning-in-raystation/

RayStation Deep Learning Dose Prediction models: 2025-05-01

ADVANCING CANCER TREATMENT